King pays Acura $3M for product license

Opioid pain medicines developed with Acura's proprietary Aversion Technology are designed to relieve moderate to severe pain and deter common methods of prescription drug abuse, including injection of dissolved tablets, snorting of crushed tablets and swallowing of excessive numbers of tablets.

King and Acura entered into an agreement in October 2007, providing King with an exclusive license to Acurox tablets for pain relief and another undisclosed opioid pain medicine. King was also given an option to license all future pain treatments formulated with Acura's Aversion Technology.

"Achieving the proof-of-concept milestone associated with this product and King's exercise of their option further demonstrates the applicability of the Aversion technology platform to a wide range of products susceptible to abuse," said Acura Chief Operating Officer Robert B. Jones.